- Exelixis recently outlined a packed schedule of presentations at the 2026 ASCO Annual Meeting in Chicago, showcasing new clinical analyses for its approved cancer drug CABOMETYX and its investigational kinase inhibitor zanzalintinib across multiple late-stage trials and tumor types.
- These data, including pivotal phase 3 results in metastatic colorectal cancer and further evidence for CABOMETYX’s role across difficult-to-treat tumors, could materially influence how investors view the depth and breadth of Exelixis’ oncology portfolio.
- We’ll now examine how the forthcoming ASCO data on zanzalintinib in colorectal cancer may reshape Exelixis’ previously balanced investment narrative.
Outshine the giants: these 12 early-stage AI stocks could fund your retirement.
Exelixis Investment Narrative Recap
To own Exelixis, you need to believe CABOMETYX can remain a strong cash generator…
